RECRUITINGOBSERVATIONAL

A Prospective Cohort Study of Myasthenia Gravis in China

Clinical Characteristics, Prognosis and Biomarkers of Myasthenia Gravis: a Prospective Cohort Study in China

About This Trial

The goal of this prospective cohort study is to investigate long-term therapeutic strategies for myasthenia gravis (MG) and identify potential biomarkers. The main questions it aims to answer are: 1. Whether low-dose oral steroids may lead to a reduction in the recurrence rate among patients with MG. 2. To identify potential biomarkers that can predict disease progression and prognosis. This study recruits well-controlled patients with MG. Based on patient preferences and considerations such as coexisting conditions (e.g., uncontrolled hypertension, diabetes, severe osteoporosis, obesity), the participants will be non-randomly divided into two groups: a maintenance steroid therapy group and a withdrawal group (withdraw all immunosuppresants). Subsequently, these groups of patients will undergo long-term follow-up assessments.

Who May Be Eligible (Plain English)

Who May Qualify: - 1: Attended the outpatient department of neurology of PUMCH from 9/30/2022 to 9/30/2024. - 2: Diagnosed as myasthenia gravis. - 3: Follow-up time at PUMCH\>6 months. - 4: The patient understood and signed the willing to sign a consent form form. Who Should NOT Join This Trial: - 1: Comorbidities with other conditions that cause skeletal muscle weakness make the clinical symptoms difficult to assess - 2: Records related to comorbidities and medications were not available at baseline and during follow-up. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * 1: Attended the outpatient department of neurology of PUMCH from 9/30/2022 to 9/30/2024. * 2: Diagnosed as myasthenia gravis. * 3: Follow-up time at PUMCH\>6 months. * 4: The patient understood and signed the informed consent form. Exclusion Criteria: * 1: Comorbidities with other conditions that cause skeletal muscle weakness make the clinical symptoms difficult to assess * 2: Records related to comorbidities and medications were not available at baseline and during follow-up.

Treatments Being Tested

DRUG

Steroid Drug

Maintaining low-dose oral steroids

OTHER

Withdraw all immunosuppresants

Locations (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China